Medical Dialogues10d
FDA Expands Approval of wearable furosomide delvery system for CKD-Related Edema
The US Food and Drug Administration (FDA) has broadened the approval of Furoscix (furosemide injection) to treat edema in ...
The American Journal of Managed Care28d
FDA Expands Furosemide Injection Label to Treat Edema in CKD
Furosemide injection was previously approved to treat congestion from fluid buildup in adults with chronic heart failure. Last year, the drug developer noted that FDA feedback from a 2023 Type D ...
Monthly Prescribing Reference28d
Wearable Furosemide Delivery System Approved for CKD Patients
Furoscix is expected to be available for CKD patients in April 2025. The Food and Drug Administration (FDA) has expanded the approval of Furoscix ® (furosemide injection) to include the treatment ...
American Association of Individual Investors3d
Why scPharmaceuticals Inc.’s (SCPH) Stock Is Down 11.41%
As of Tuesday, April 01, scPharmaceuticals Inc.’s SCPH share price has dipped by 11.41%, which has investors questioning if this is right time to buy.
Hosted on MSN27d
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for Furoscix(furosemide), expanding its indication to include oedema treatment ...